KALA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
KALA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Kala Bio's change in receivables for the quarter that ended in Dec. 2023 was $0.00 Mil. It means Kala Bio's Accounts Receivable stayed the same from Sep. 2023 to Dec. 2023 .
Kala Bio's change in receivables for the fiscal year that ended in Dec. 2023 was $0.08 Mil. It means Kala Bio's Accounts Receivable declined by $0.08 Mil from Dec. 2022 to Dec. 2023 .
Kala Bio's Accounts Receivable for the quarter that ended in Dec. 2023 was $0.12 Mil.
Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Kala Bio's liquidation value for the three months ended in Dec. 2023 was $2.54 Mil.
The historical data trend for Kala Bio's Change In Receivables can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kala Bio Annual Data | |||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||||||
Change In Receivables | Get a 7-Day Free Trial | -11.56 | 1.96 | -5.76 | 15.14 | 0.08 |
Kala Bio Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Change In Receivables | Get a 7-Day Free Trial | -0.01 | 0.08 | - | - | - |
Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.
Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.08 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kala Bio (NAS:KALA) Change In Receivables Explanation
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
Kala Bio's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:
Days Sales Outstanding | |||||
= | Accounts Receivable | / | Revenue | * | Days in Period |
= | 0.117 | / | 0 | * | 91 |
= |
2. In Ben Graham's calculation of liquidation value, Kala Bio's accounts receivable are only considered to be worth 75% of book value:
Kala Bio's liquidation value for the quarter that ended in Dec. 2023 is calculated as:
Liquidation Value | |||||||
= | Cash, Cash Equivalents, Marketable Securities | - | Total Liabilities | + | (0.75 * Accounts Receivable) | + | (0.5 * Total Inventories) |
= | 50.895 | - | 48.445 | + | 0.75 * 0.117 | + | 0.5 * 0 |
= | 2.54 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Kala Bio's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.
Todd Bazemore | officer: Chief Operating Officer | C/O DYAX CORP., 55 NETWORK DRIVE, BURLINGTON MA 01803 |
Romulus K Brazzell | officer: Chief Medical Officer | C/O INSPIRE PHARMACEUTICALS, INC., 4222 EMPEROR BLVD., SUITE 200, DURHAM NC 27703 |
Eric Trachtenberg | officer: See Remarks | 1414 RALEIGH ROAD, SUITE 400, CHAPEL HILL NC 27517 |
Darius Kharabi | officer: CHIEF BUSINESS OFFICER | C/O KALA PHARMACEUTICALS, INC., 490 ARSENAL WAY, SUITE 120, WATERTOWN MA 02472 |
Mark T Iwicki | director, officer: Chief Executive Officer | 84 WATERFORD DRIVE, MARLBOROUGH MA 01752 |
Mary Reumuth | officer: Chief Financial Officer | 100 BEAVER STREET, SUITE 201, WALTHAM MA 02453 |
Marjan Farid | director | C/O KALA PHARMACEUTICALS, INC., 1167 MASSACHUSETTS AVENUE, ARLINGTON MA 02476 |
Ra Capital Healthcare Fund Lp | director, 10 percent owner | 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
Mark S. Blumenkranz | director | C/O 1LIFE HEALTHCARE, INC., ONE EMBARCADERO CENTER, SUITE 1900, SAN FRANCISCO CA 94111 |
Hongming Chen | officer: Chief Scientific Officer | 100 BEAVER STREET, SUITE 201, WALTHAM MA 02453 |
C. Daniel Myers | director | 6120 WINDWARD PARKWAY, SUITE 290, ALPHARETTA GA 30005 |
Gregory Grunberg | director | 100 BEAVER STREET, WALTHAM MA 02453 |
Rajeev M. Shah | director | 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
Peter Kolchinsky | director, 10 percent owner | 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
Ra Capital Management, L.p. | director, 10 percent owner | 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
From GuruFocus
By Value_Insider Value_Insider • 10-20-2022
By Value_Insider Value_Insider • 11-28-2022
By sperokesalga sperokesalga • 04-12-2023
By PurpleRose PurpleRose • 08-08-2022
By Marketwired • 08-02-2023
By GuruFocusNews GuruFocusNews • 07-07-2022
By PurpleRose PurpleRose • 07-11-2022
By GuruFocusNews GuruFocusNews • 07-08-2022
By Marketwired • 08-04-2023
By Marketwired • 09-20-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.